Last reviewed · How we verify
NCT04011215: DESSINE2
Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)
NA trial testing wool clothing in Dermatitis, Atopic in 19 participants. Completed in 31 October 2024.
31 October 2024
Quick facts
| Lead sponsor | Murdoch Childrens Research Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 23 September 2019 |
| Primary completion | 31 October 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- wool clothing
- standard clothing
Conditions studied
- Dermatitis, Atopic — all drugs for Dermatitis, Atopic →
Sponsor
Murdoch Childrens Research Institute
Who can join
Adults 3 Months to 5, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a sequentially recruited, cross-over-cohort, outpatient-based evaluation of the effectiveness of wool clothing, as compared to standard clothing, in reducing the severity of childhood atopic dermatitis (eczema) over two consecutive six-week periods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04011215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dermatitis, Atopic
Currently open trials in the same condition.
- NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
- NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
- NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting
Other Murdoch Childrens Research Institute trials
Trials by the same sponsor.
- NCT07251790 — Optimising Breathing Support at Extubation in Very Preterm Infants: A Clinical Study · NA · not yet recruiting
- NCT07136584 — SOS for Caregiver Wellbeing · NA · recruiting
- NCT06686446 — Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial · NA · terminated
- NCT06992141 — A Strep Throat Controlled Human Infection Trial in Healthy Adults · EARLY_PHASE1 · completed
- NCT06186141 — Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04011215 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Murdoch Childrens Research Institute
- Last refreshed: 25 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04011215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing